Ramos/Cre cells are derived from the human B lymphocyte cell line Ramos by stably integration of a constitutive Cre recombinase stably expression construct. Ramos cell line was generated from a human Burkitt′s lymphoma which does not possess the EBV genome, has been widely used in cancer research, virus study and drug development.  Ramos cells express CD19, CD20, and other B-cell markers, making them a useful model for B-cell studies and test the efficacy of monoclonal antibodies and CAR T-cell therapies targeting B-cell malignancies. Ramos/Cre cells stably express a nuclear localized Cre recombinase under the control of a CMV promoter.